Carrico J, Jia X, Zhao Y, et al. Cost-effectiveness, budget impact of tildrakizumab for the treatment of moderate to severe plaque psoriasis using 2019 drug costs [abstract L14]. J Manag Care Spec Pharm. 2019, 25(suppl 10-a):S79. doi: 10.18553/jmcp.2019.25.10-a.s1
Advertisement
Articles by Carrico J, Jia X, Zhao Y, et al. Cost-effectiveness, budget impact of tildrakizumab for the treatment of moderate to severe plaque psoriasis using 2019 drug costs [abstract L14]. J Manag Care Spec Pharm. 2019, 25(suppl 10-a):S79. doi: 10.18553/jmcp.2019.25.10-a.s1
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves Once-Monthly Subcutaneous Olanzapine for Schizophrenia
2
A New Mechanism for DME in the BRUNELLO Trial: Donald J. D’Amico, MD
3
Using Complement Inhibitors in GA Comes With Pros and Cons
4
Full POLARGO Data Reveal OS, Safety for Pola-R-GemOx in DLBCL
5